Results 11 to 20 of about 19,801 (209)
Comparison of the IHC markers CD138 and CD43 in oral leukoplakia: An original research
Journal of Pharmacy and Bioallied Sciences, 2023 Background: In the clinical practice, one of the most common suspicious lesions that may be potentially malignant is oral leukoplakia. Globally, the rate at which it turns malignant varies.
Anitha Akkaloori +5 more
doaj +1 more source
Syndecan-1 (CD138), Carcinomas and EMT [PDF]
International Journal of Molecular Sciences, 2021 Cell surface proteoglycans are known to be important regulators of many aspects of cell behavior. The principal family of transmembrane proteoglycans is the syndecans, of which there are four in mammals. Syndecan-1 is mostly restricted to epithelia, and bears heparan sulfate chains that are capable of interacting with a large array of polypeptides ...
openaire +4 more sources
BMC Research Notes, 2022 Objective Inflammation is present in many diseases and identification of immune cell infiltration is a common assessment. CD138 (syndecan-1) is a recommended immunohistochemical marker for human plasmacytes although it is also expressed in various ...
David K. Meyerholz +9 more
doaj +1 more source
CD138− plasma cell myeloma [PDF]
Blood, 2019 ![Figure][1] A 69-year-old man with a history of CD138− plasma cell myeloma (PCM) who received chemotherapy regimens and stem cell transplant presented for bone marrow biopsy, which revealed sheets of atypical plasma cells with abundant amphophilic cytoplasm, occasional binucleation ...
Wen Shuai, Shaoying Li
openaire +2 more sources
Macrophage Inhibitory Factor-1 (MIF-1) controls the plasticity of multiple myeloma tumor cells. [PDF]
PLoS ONE, 2018 Multiple Myeloma (MM) is the second most common hematological malignancy with a median survival of 5-10 years. While current treatments initially cause remission, relapse almost always occurs, leading to the hypothesis that a chemotherapy-resistant ...
Danielle Joseph +2 more
doaj +1 more source
Tumor-initiating capacity of CD138− and CD138+ tumor cells in the 5T33 multiple myeloma model [PDF]
Leukemia, 2012 Tumor-initiating capacity of CD138− and CD138+ tumor cells in the 5T33 multiple myeloma ...
Van Valckenborgh, Els +12 more
openaire +3 more sources
Frontiers in Immunology, 2020 CD138 (syndecan 1), a member of the heparan-sulfate proteoglycan family, regulates diverse biological responses by interacting with chemokines, cytokines, growth factors, and adhesion molecules.
Lunhua Liu +2 more
doaj +1 more source
Isolated maxillary sinus plasmacytoma: A rare entity
Journal of Marine Medical Society, 2023 Plasmacytoma is a monoclonal plasma B cell malignancy originating in either bone named as solitary plasmacytoma of the bone or in soft tissue labeled as extramedullary plasmacytoma (EMP). Solitary EMP is rare accounting for
Tanuj Madan +3 more
doaj +1 more source
CD10 and CD138 can be expressed in giant cell tumor of bone: An immunohistochemical study
Avicenna Journal of Medicine, 2016 Giant cell tumor of bone (GCTB) is a primary bone neoplasm which is characterized by the presence of mononuclear cells (MCs) and osteoclast-like multinucleated giant cells (MNGCs).
Mousa A Al-Abbadi +5 more
doaj +1 more source
CD138 expression is a molecular signature but not a developmental requirement for RORγt+ NKT17 cells
JCI Insight, 2021 Invariant NKT (iNKT) cells are potent immunomodulatory cells that acquire effector function during their development in the thymus. IL-17–producing iNKT cells are commonly referred to as NKT17 cells, and they are unique among iNKT cells to express the ...
Shunqun Luo +4 more
doaj +1 more source